OMERS ADMINISTRATION Corp Sells 54,352 Shares of Kenvue Inc. (NYSE:KVUE)

OMERS ADMINISTRATION Corp reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 8.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 571,329 shares of the company's stock after selling 54,352 shares during the period. OMERS ADMINISTRATION Corp's holdings in Kenvue were worth $12,198,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in KVUE. Grove Bank & Trust grew its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. increased its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Asset Planning Inc bought a new position in shares of Kenvue during the 4th quarter valued at about $42,000. Finally, Clarity Asset Management Inc. bought a new position in shares of Kenvue during the 4th quarter valued at about $45,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Trading Up 1.1%

NYSE KVUE traded up $0.27 on Friday, reaching $24.15. The company had a trading volume of 19,921,749 shares, compared to its average volume of 16,552,309. The firm has a market cap of $46.34 billion, a price-to-earnings ratio of 45.57, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The business has a 50 day moving average of $23.15 and a two-hundred day moving average of $22.58.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period in the previous year, the firm earned $0.28 earnings per share. The firm's quarterly revenue was down 3.9% on a year-over-year basis. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.40%. Kenvue's payout ratio is 149.09%.

Analysts Set New Price Targets

KVUE has been the topic of several research reports. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Barclays increased their target price on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday. Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada restated a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, Piper Sandler lifted their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Kenvue currently has an average rating of "Hold" and a consensus price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.